Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 38

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 38
---
     |       |     |             |    (150,000 | ) |     | -B    |     |           |             |   |
|                                                                                                                                                                                                                              |     |                     |             |   |     |               |             |   |     |             |         |   |     |       |     |             |  74,455,306 |   |     | -I    |     |           |             |   |
| Foreign currency translation/Accumulated other comprehensive loss                                                                                                                                                            |     |                     |  (2,039,946 | ) |     |               |     108,853 |   |     |             |       — |   |     |       |     |             |    (108,853 | ) |     | -I    |     |           |  (2,093,946 | ) |
| Total shareholders’ (deficit) equity                                                                                                                                                                                         |     |                     | (15,080,960 | ) |     |               |   2,882,507 |   |     |             |       — |   |     |       |     |             |  31,715,757 |   |     |       |     |           |  22,905,312 |   |
| Total Liabilities and Shareholders’ (Deficit) Equity                                                                                                                                                                         |     | $                   |     460,853 |   |     | $             |   4,337,628 |   |     | $           |       — |   |     |       |     | $           |  18,106,831 |   |     |       |     | $         |  22,905,595 |   |

The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

23

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
UNAUDITED CONDENSED CONSOLIDATED PRO FORMA STATEMENTS OF OPERATIONS

|                                                                                                               |     | For the Six Months Ended June 30, 2025 |             |               |     |   |            |             |     |   |           |       |     |           |     |   |            |   |
|:--------------------------------------------------------------------------------------------------------------|:----|:---------------------------------------|------------:|:--------------|:----|:--|-----------:|:------------|:----|:--|----------:|:------|:----|:----------|:----|:--|